Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
Sponsor: Alison Stopeck
Summary
The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
Official title: Double-blind, Randomized Phase II Clinical Trial of Sulindac for Reducing Breast Density in Postmenopausal Women at Risk of Developing Breast Cancer
Key Details
Gender
FEMALE
Age Range
35 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
61
Start Date
2020-11-20
Completion Date
2025-05-19
Last Updated
2026-07-17
Healthy Volunteers
No
Conditions
Interventions
Sulindac Pill
Randomized participants will receive either 150 mg oral sulindac twice daily.
Placebo
placebo pills twice daily
Locations (2)
Cedars Sinai - Cancer
Los Angeles, California, United States
Stony Brook University Cancer Center
Stony Brook, New York, United States